Stem cell transplantation for primary immunodeficiency diseases: The North American experience

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 6, 2014, Pages 521-526

  Pai, Sung Yun ^a,b,c   Cowan, Morton J ^d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic granulomatous disease; Hematopoietic stem cell transplantation; Immune reconstitution; Severe combined immunodeficiency; Wiskott Aldrich syndrome

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHRONIC GRANULOMATOUS DISEASE; HUMAN; INFECTION; NEWBORN SCREENING; NORTH AMERICA; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME; ALLOGRAFT; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INFANT; MALE; MORTALITY; NEWBORN; PROCEDURES; SURVIVAL RATE; UNITED STATES; WISKOTT-ALDRICH SYNDROME;

ALLOGRAFTS; COMMON VARIABLE IMMUNODEFICIENCY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; UNITED STATES; WISKOTT-ALDRICH SYNDROME;

EID: 84927697326     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000115     Document Type: Review

References (45)

1. Gatti RA, Meuwissen HJ, Allen HD, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2:1366-1369.
2. Parkman R, Gelfand EW, Rosen FS, et al. Severe combined immunodeficiency and adenosine deaminase deficiency. N Engl J Med 1975; 292:714-719.
3. O'Reilly RJ, Dupont B, Pahwa S, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977; 297:1311-1318.
4. Reisner Y, Kapoor N, Kirkpatrick D, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983; 61:341-348.
5. Cowan MJ, Wara DW, Weintrub PS, et al. Haploidentical bone marrow transplantation for severe combined immunodeficiency disease using soybean agglutinin-negative, T-depleted marrow cells. J Clin Immunol 1985; 5:370-376.
6. Buckley RH, Schiff SE, Sampson HA, et al. Development of immunity in human severe primary T cell deficiency following haploidentical bone marrow stem cell transplantation. J Immunol 1986; 136:2398-2407.
7. Bach FH, Albertini RJ, Joo P, et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968; 2:1364-1366.
8. Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med 1978; 298:921-927.
9. Kapoor N, Kirkpatrick D, Blaese RM, et al. Reconstitution of normal mega-karyocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide. Blood 1981; 57:692-696.
10. Antoine C, Müller S, Cant A, et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience. Lancet 2003; 361:553-560.
11. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999; 340:508-516.
12. Patel DD, Gooding ME, Parrott RE, et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med 2000; 342:1325-1332.
13. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or posttransplant GVHD prophylaxis. J Pediatr 2009; 155:834-840; e1.
14. Grunebaum E, Mazzolari E, Porta F, et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295:508-518.
15. Griffith LM, Cowan MJ, Kohn DB, et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 2008; 122:1087-1096.
16. Griffith LM, Cowan MJ, Notarangelo LD, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 2009; 124:1152-1160; e12.
17. Griffith LM, Cowan MJ, Notarangelo LD, et al. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 2014; 133:335-347.
18. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 2002; 99:872-878.
19. Brown L, Xu-Bayford J, Allwood Z, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 2011; 117:3243-3246.
20. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602-610.
21. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005; 115:391-397.
22. Routes JM, Grossman WJ, Verbsky J, et al. Statewide newborn screening for severe T-cell lymphopenia. JAMA 2009; 302:2465-2470.
23. Hale JE, Bonilla FA, Pai S-Y, et al. Identification of an infant with severe combined immunodeficiency by newborn screening. J Allergy Clin Immunol 2010; 126:1073-1074.
24. Kwan A, Church JA, Cowan MJ, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol 2013; 132:140-141.
25. Shearer WT, Dunn E, Notarangelo LD, et al. Establishing diagnostic criteria for SCID, leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 2014; 133:1092-1098.
26. Dvorak CC, Cowan MJ, Logan BR, et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the primary immune deficiency treatment consortium prospective study 6901. J Clin Immunol 2013; 33:1156-1164.
27. Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol 2013; 131:994-1000.
28. Pai S-Y, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency. N Engl J Med 2014; 371:434-446.
29. Li L, Moshous D, Zhou Y, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002; 168:6323-6329.
30. De Villartay J-P. V(D)J recombination deficiencies. Adv Exp Med Biol 2009; 650:46-58.
31. van der Burg M, Ijspeert H, Verkaik NS, et al. A DNA-PKcs mutation in a radiosensitive T-B-SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest 2009; 119:91-98.
32. Enders A, Fisch P, Schwarz K, et al. A severe form of human combined immunodeficiency due to mutations in DNA ligase IV. J Immunol 2006; 176:5060-5068.
33. O'Marcaigh AS, Desantes K, Hu D, et al. Bone marrow transplantation for T-B-severe combined immunodeficiency disease in Athabascan-speaking native Americans. Bone Marrow Transplant 2001; 27:703-709.
34. Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood 2014; 123:281-289.
35. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res 2011; 49:25-43.
36. Dvorak CC, Hassan A, Slatter MA, et al. Comparison of outcomes of hemato-poietic stem cell transplantation without chemotherapy conditioning by using matchedsiblingandunrelateddonorsfortreatmentofseverecombinedimmuno-deficiency. J Allergy Clin Immunol 2014; pii: S0091-6749(14)00886-0. [Epub ahead of print]
37. Moratto D, Giliani S, Bonfim C, et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hema-topoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011; 118:1675-1684.
38. Shin CR, Kim M-O, Li D, et al. Outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome. Bone Marrow Transplant 2012; 47:1428-1435.
39. Zhu Q, Zhang M, Blaese RM, et al. The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene. Blood 1995; 86:3797-3804.
40. Ozsahin H, Cavazzana-Calvo M, Notarangelo LD, et al. Long-term outcome following hematopoietic stem cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and the European Group for Blood and Marrow Transplantation. Blood 2007; 111:439-465.
41. Kang EM, Marciano BE, DeRavin S, et al. Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol 2011; 127:1319-1328.
42. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulo-matous disease with myeloablative conditioning and an unmodified hemo-poietic allograft: a survey of the European experience. Blood 2002; 100:4344-4350.
43. Martinez CA, Shah S, Shearer WT, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012; 129:176-183.
44. Tewari P, Martin PL, Mendizabal A, et al. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant 2012; 18:1368-1377.
45. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363:2600-2610.